Results 201 to 210 of about 288,150 (296)

Malignant bowel obstruction related to advanced peritoneal metastases: survival outcomes of surgical treatment. [PDF]

Pleura Peritoneum
Scarsi S, Teixeira Farinha H, Kefleyesus A, Hübner M, Clerc D.   +4 more
europepmc   +1 more source

Synergistic Regulation of Biomaterials and Macrophages: A Novel Paradigm in Immunotherapy

MedComm – Biomaterials and Applications, Volume 5, Issue 4, December 2026.
Bioengineered materials mediating the modulation of macrophage plasticity and inflammatory signals in the tumor microenvironment effectively remodel immunoregulatory states, boost antitumor immunity, and promote tissue repair, achieving synergistic therapeutic outcomes.
Jiayu Zhang, Songhang Xing, Shanshan Zhang, Yuan Hao, Xiaojie Qu, Wurihan Bao, Manwei Hao, Han Sun, Mingyuan Dong, Huiling Zhang, Dan Huang, Yiqi Wang, Xuanjie Jiang, Xiaoyu Pu, Yanyan Chi, Xingtong Wang, Xuefeng Li   +16 more
wiley   +1 more source

Case Report: Dramatic response to amivantamab plus chemotherapy in EGFR G719A-mutant lung adenocarcinoma with liver and peritoneal metastases. [PDF]

Front Oncol
Kim J, Kim HG, Lee SH.
europepmc   +1 more source

Total Neoadjuvant Treatment for Esophageal Adenocarcinoma With Oligometastases: TNT‐OES‐1 Trial

International Journal of Cancer, Volume 159, Issue 10, Page 2552-2561, 15 November 2026.
Total neoadjuvant therapy could combine the potentially strong systemic effect of FLOT chemotherapy with the good locoregional control of CROSS chemoradiotherapy. While total neoadjuvant therapy is increasingly used in rectal cancer, its potential in gastroesophageal cancer remains largely unexplored.
Charlène J. van der Zijden, Tamara J. Huizer, Ben M. Eyck, Ate van der Gaast, Leni van Doorn, Marjolein Y. V. Homs, J. Jan B. van Lanschot, Joost J. M. E. Nuyttens, Lindsey Oudijk, Manon C. W. Spaander, Bas P. L. Wijnhoven, Bianca Mostert, Sjoerd M. Lagarde   +12 more
wiley   +1 more source

Optimization of spectral photon-counting CT reconstruction parameters for improved detection of peritoneal metastases compared with energy-integrating detector dual-energy CT: a phantom study. [PDF]

Eur Radiol Exp
Greffier J, Grange R, Dabli D, Houmeau A, Antonuccio MN, Rousset P, Si-Mohamed S.   +6 more
europepmc   +1 more source

Investigating Risk Factors for Delayed Melanoma Recurrence Beyond 5 Years Post‐Primary Tumor Diagnosis

Cancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Patients undergoing treatment for cutaneous melanoma are generally considered cured after a period of 5 years, since most recurrences manifest within three to 5 years. However, some patients can present with a delayed recurrence of melanoma beyond a 10‐year timeframe.
Kaspar Itin, Rebecca Lapides, Soumya Paria, Babak Saravi, Alina. M. Torrez, Lara Valeska Maul, Michael Wang‐Evers, Alexander A. Navarini, Dieter Manstein, Beata Kun, Leticia Szadai, Judit Olàh, Eszter Baltas, Rolland Gyulai, Peter Hollo, Grzegorz Sarek, Istvan B. Németh, Kaustubh Adhikari, Elisabeth Roider   +18 more
wiley   +1 more source

Impact of Omission of Hyperthermic Intraperitoneal Chemotherapy for Treatment of Colorectal Peritoneal Metastases. [PDF]

Perm J
Im K, Yoshinaga S, Leung AM.
europepmc   +1 more source

Administrative Workload and Associated Distress in Individuals Undergoing Cancer Therapy

Cancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Introduction Cancer care is burdensome, but patient experience with time and administrative burdens is variable. Our objective was to assess the association between daily administrative tasks, time spent, and reported burden and identify demographic and clinical predictors.
Sarah J. Boyle, Helen M. Parsons, Michael Anne Kyle, Patricia Jewett, Guang Yang, Zuofu Huang, Arjun Gupta, Deanna Teoh, Yingling Fan, Anne Blaes, Rebecca Arend, Gabrielle B. Rocque, Julian Wolfson, Rachel I. Vogel   +13 more
wiley   +1 more source

Stage IV Ovarian Cancer Is Not Uniformly Lethal: Two Subgroups With Stage II‐Like Outcomes Identified in Large Retrospective Cohorts

Cancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background The International Federation of Gynecology and Obstetrics (FIGO) staging system for advanced ovarian cancer has remained largely static since 2014, with stage IV subdivided into IVA and IVB without further stratification. Emerging evidence suggests substantial prognostic heterogeneity within stage IV, yet large‐scale validation ...
Cheng Fang, Jundong Li, Qiaqia Li
wiley   +1 more source